

CORRECTION

Open Access



Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Marion Alcantara^{1,2}, Marion Chevrier³, Fabrice Jardin⁴, Anna Schmitt⁵, Caroline Houillier⁶, Lucie Oberic⁷, Olivier Chinot⁸, Franck Morschhauser⁹, Frédéric Peyrade¹⁰, Roch Houot¹¹, Khê Hoang-Xuan⁶, Hervé Ghesquieres¹² and Carole Soussain^{2,13*}

Correction: *Journal of Hematology & Oncology* (2024) 17:86

<https://doi.org/10.1186/s13045-024-01606-w>

Published online: 19 October 2024

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The authors' names in the authorship of the original article were mistakenly inverted and have since been amended.

The online version of the original article can be found at <https://doi.org/10.1186/s13045-024-01606-w>.

*Correspondence:

Carole Soussain
carole.soussain@curie.fr

¹CellAction, Center for Cancer Immunotherapy, Institut Curie, Suresnes, France

²Clinical Hematology Unit, Institut Curie, Saint-Cloud 92210, France

³Department of Biostatistics, Institut Curie, Saint-Cloud 92210, France

⁴Department of Clinical Hematology and INSERM U1245, Centre Henri Becquerel, Rouen, France

⁵Service d'Hématologie, Institut Bergonié, Bordeaux, France

⁶Neurooncology Department, Assistance Publique – Hôpitaux de Paris (APHP), Sorbonne Université, IHU, ICM, Groupe Hospitalier Pitié-Salpêtrière, Paris, France

⁷Hematology, Institut Universitaire du Cancer de Toulouse Oncopôle, Toulouse, France

⁸AP-HM, Service de Neuro-Oncologie, CHU de la Timone, Aix-Marseille Université, CNRS, INP, Marseille Cedex, France

⁹Univ. Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille F-59000, France

¹⁰Service d'Onco-hématologie, Centre Hospitalier Simone Veil, Cannes, France

¹¹Department of Hematology, University Hospital of Rennes, UMR U1236, INSERM, University of Rennes, French Blood Establishment, Rennes, France

¹²Department of Hematology, Hôpital Lyon Sud, Claude Bernard Lyon 1 University, Pierre- Bénite, France

¹³Center for Cancer Immunotherapy, Institut Curie, PSL Research University, INSERM U932, Paris 75005, France



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.